Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biodel Files NDA For VIAject
Biodel has submitted a new drug application (NDA) to the FDA for clearance to market VIAject as a treatment for diabetes. VIAject is Biodel’s proprietary formulation of recombinant
Biodel has submitted a new drug application (NDA) to the FDA for clearance to market VIAject as a treatment for diabetes. VIAject is Biodel’s proprietary formulation of recombinant
Anika Therapeutics (Anika) has acquired Fidia Advanced Biopolymers, (FAB), a wholly-owned subsidiary of Fidia Farmaceutici. Anika will develop its own direct US sales capability to capture higher margins
D-Pharm has reported enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI) at the Wolfson Medical Center, Israel. The MACSI trial
Basilea Pharmaceutica has reported that the FDA has issued to the sponsor, Johnson & Johnson Pharmaceutical Research and Development (Johnson & Johnson PRD), a Complete Response Letter on
Santarus has submitted an Investigational New Drug (IND) application to FDA requesting approval to begin a phase III clinical program evaluating Rifamycin SV MMX in patients with travelers’
Meda has reported that it has expanded its collaboration with the French development company, Etypharm for the patented product, Axorid. The company said that new territories such as
Seahorse Bioscience has provided update on its XF96 Extracellular Flux Analyzer, used for measuring cellular bioenergetics. The company said that a panel of scientific experts assembled by ‘TheScientist’
Echo Therapeutics has provided updates on the development of its needle-free Prelude SkinPrep System for transdermal drug delivery. The company is developing it as a platform technology for
Cleveland BioLabs (CBLI) has entered into a 50/50 joint venture with Bioprocess Capital Ventures to develop the company’s Curaxin compounds for cancer applications. As per the agreement, CBLI
QLT has acquired OT-730 from Othera Pharmaceuticals and its wholly-owned subsidiary, Othera Holding, (together, Othera) for a one-time payment of $7.5m in cash. OT-730 is a prodrug of